Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.

Abstract:

:Lysosome-associated membrane protein-1 is a protein with a significant content of beta1,6-branched N-glycans. It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelial cells. The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression. The expression of lysosome-associated membrane protein-1 was for the first time determined immunohistochemically in formalin-fixed paraffin-embedded specimens comprising 42 primary cutaneous melanomas, 15 lymph node melanoma metastases (11 correlated with primary tumours), three melanoma recurrences (correlated with both primary and metastatic melanomas), 27 nevi and four epithelial tumours (two seborrhoeic keratoses and two basal cell carcinomas). Our results demonstrate that development and progression of melanoma are associated with changes of the lysosome-associated membrane protein-1 level. The expression was strongest in melanoma recurrences and lymph node metastases, weaker in primary cutaneous melanomas and not detectable in melanocytes of pigmented nevi. Nodular melanomas expressed lysosome-associated membrane protein-1 at higher level than superficially spreading melanomas.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Kuźbicki L,Gajo B,Chwirot BW

doi

10.1097/01.cmr.0000215034.00318.7a

subject

Has Abstract

pub_date

2006-06-01 00:00:00

pages

235-43

issue

3

eissn

0960-8931

issn

1473-5636

pii

00008390-200606000-00005

journal_volume

16

pub_type

杂志文章
  • Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.

    abstract::Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000505

    authors: Diamantopoulos PT,Stoungioti S,Anastasopoulou A,Papaxoinis G,Gogas H

    更新日期:2018-12-01 00:00:00

  • Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.

    abstract::High-dose cisplatin regimens have been shown to be highly active in advanced melanoma patients but are associated with unacceptable side effects. In order to increase the platinum dose but avoid severe side effects, we treated 15 dacarbazine (DTIC)-resistant metastatic melanoma patients with a combination regimen of c...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200108000-00012

    authors: Güven K,Kittler H,Wolff K,Pehamberger H

    更新日期:2001-08-01 00:00:00

  • A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

    abstract::A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/CMR.0000000000000556

    authors: Block MS,Nevala WK,Pang YP,Allred JB,Strand C,Markovic SN

    更新日期:2019-08-01 00:00:00

  • Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy.

    abstract::Electrochemotherapy (ECT), chemotherapy administered in combination with electric fields, has the potential to be an effective localized treatment for cutaneous malignancies. Bleomycin's cytotoxicity was enhanced by exposing tumour cells to electrical fields following intravenous injection of the chemotherapeutic agen...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199702000-00003

    authors: Heller R,Jaroszeski M,Perrott R,Messina J,Gilbert R

    更新日期:1997-02-01 00:00:00

  • Accuracy of sentinel lymph node dissection for melanoma staging in the presence of a collision tumour with a lymphoproliferative disease.

    abstract::Sentinel lymph node dissection (SLND) identifies melanoma patients with metastatic disease who would benefit from radical lymph node dissection (RLND). Rarely, patients with melanoma have an underlying lymphoproliferative disease, and melanoma metastases might develop as collision tumours in the sentinel lymph node (S...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000098

    authors: Gero D,Queiros da Mota V,Boubaker A,Berthod G,de Leval L,Demartines N,Matter M

    更新日期:2014-08-01 00:00:00

  • Selective in vivo and in vitro incorporation and accumulation of phenolic thioether amine into malignant melanoma and identification of a (58 kD) binding glycoprotein.

    abstract::Our previous in vivo studies indicated that a phenolic thioether amine (PTEA), 4-S-cysteaminylphenol (CAP), selectively disintegrates melanocytes of black hair and skin, and inhibits the growth of murine and human malignant melanomas. To elucidate the mechanism of the in vivo melanocytotoxicity and anti-melanoma effec...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199211000-00002

    authors: Yamada K,Jimbow K

    更新日期:1992-11-01 00:00:00

  • Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.

    abstract::Dermatologic toxicity is a known reaction of ipilimumab and vemurafenib. Because of the lack of effective treatments and aggressive nature of melanoma, treatments are often discontinued and new treatments are initiated in rapid succession. We report what we believe to be the first case of cumulative dermatologic toxic...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000018

    authors: Ludlow SP,Pasikhova Y

    更新日期:2013-12-01 00:00:00

  • Fatty acid receptor GPR120: a novel marker for human melanoma.

    abstract::The correlation between ultraviolet radiation of the skin and melanoma incidence in humans is well established. Interestingly, epidemiologic data suggest also a correlation to an increased BMI pointing to metabolic trigger factors in melanoma pathogenesis. To substantiate this connection, we studied the expression of ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000445

    authors: Kleemann J,Hrgovic I,Ter-Nedden J,Kleimann P,Steinhorst K,Härle K,Müller J,Kaufmann R,Meissner M,Kippenberger S

    更新日期:2018-08-01 00:00:00

  • Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells.

    abstract::Melanoma cells are unusual because, unlike most epithelial tumours, constitutive expression of HLA class II antigens is common. We have previously demonstrated that a peptide-specific CD4+ T-cell clone proliferates briskly in response to peptide and HLA class II expressing melanoma cell lines derived from metastases. ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199904000-00010

    authors: Brady MS,Eckels DD,Lee F,Ree SY,Lee JS

    更新日期:1999-04-01 00:00:00

  • Blood DNA methylation, nevi number, and the risk of melanoma.

    abstract::Germline mutations determining increased cutaneous malignant melanoma (CMM) risk have been identified in familial and sporadic CMM cases, but they account only for a small proportion of CMM cases. Recent evidence suggests that germline epimutations (e.g. DNA methylation alterations), which can be inherited similarly t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000112

    authors: Pergoli L,Favero C,Pfeiffer RM,Tarantini L,Calista D,Cavalleri T,Angelici L,Consonni D,Bertazzi PA,Pesatori AC,Landi MT,Bollati V

    更新日期:2014-10-01 00:00:00

  • Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.

    abstract::Downstream of Ras, the serine/threonine kinase B-raf has been reported to be mutated, amongst other carcinomas, in a substantial subset of primary melanomas, with a preponderance of mutations within the kinase domain, including the activating V599E and V599K transitions. We investigated a representative series of 54 r...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200510000-00011

    authors: Kirschner M,Helmke B,Starz H,Benner A,Thome M,Deichmann M

    更新日期:2005-10-01 00:00:00

  • Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.

    abstract::The aim of this study was to present the epidemiological, clinicopathological, and treatment characteristics of patients diagnosed and treated in a tertiary referral center and to analyze independent factors associated with these characteristics. In this cohort study, epidemiological, clinicopathological, and treatmen...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000456

    authors: Tsoutsos D,Papadopoulos S,Kehagias G,Mara A,Kyriopoulou E,Karonidis A,Spiliopoulos K,Mpalitsaris E,Karapiperis G,Panayotou P,Papaliodi E,Choreftaki T,Papaxoinis G,Benopoulou O,Ioannovich J,Gogas H

    更新日期:2018-08-01 00:00:00

  • Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.

    abstract::Seasonal variation in melanoma diagnoses has been observed in numerous studies that used calendar time indicators. Depending on the latitude (and altitude) of the study region, the magnitude of seasonal and year-to-year variation of ultraviolet radiation (UVR) is neglected in these studies. An alternative approach com...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000205

    authors: Keller AK,Uter W,Pfahlberg AB,Radespiel-Tröger M,Mayer I,Gefeller O

    更新日期:2015-12-01 00:00:00

  • Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth.

    abstract::Melanoma tumors have been shown to comprise both invasive and proliferative cell subpopulations. These populations are highly plastic, thus hampering full characterization and therapeutic targeting of dormant and partially dedifferentiated invasive cells. We have reported, previously, that melanoma cells grown in a se...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328351e7c4

    authors: Ghislin S,Deshayes F,Lauriol J,Middendorp S,Martins I,Al-Daccak R,Alcaide-Loridan C

    更新日期:2012-06-01 00:00:00

  • Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis.

    abstract::The Eastern Cooperative Oncology Group consensus guidelines from 2016 recommend interruption of targeted therapy with BRAF- and MEK-inhibitors during radiotherapy with data being based mostly on BRAF monotherapy. The aim of this study is to provide data on the safety of concurrent radiotherapy and combination targeted...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000682

    authors: Ziegler JS,Kroeze S,Hilbers ML,Imhof L,Guckenberger M,Levesque MP,Dummer R,Cheng P,Mangana J

    更新日期:2020-12-01 00:00:00

  • Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds.

    abstract::Ultraviolet-B (UV-B) triggers a cascade of events involving cell cycle control genes leading ultimately to DNA repair or apoptosis. The hypothesis examined here is that the genetic abnormality predisposing to melanoma affects the ability of the cell to respond appropriately to UV-B, so favouring mutagenesis. Epstein-B...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200102000-00001

    authors: Shannon JA,Kefford RF,Mann GJ

    更新日期:2001-02-01 00:00:00

  • Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment.

    abstract::Melanomas contain subsets of cancer stem-like cells with tumor-initiating capacity. The frequency of these cells in the tumor is still a topic of debate. We investigated the phenotypic plasticity of cancer cells grown as melanospheres to elucidate the influence of the microenvironment on some features of melanoma stem...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283531317

    authors: Sztiller-Sikorska M,Koprowska K,Jakubowska J,Zalesna I,Stasiak M,Duechler M,Czyz ME

    更新日期:2012-06-01 00:00:00

  • Determinants of acute regional toxicity following isolated limb perfusion for melanoma.

    abstract::Hyperthermic isolated limb perfusion (ILP) with melphalan is well established as an effective form of treatment for recurrent melanoma confined to an extremity. High drug concentrations in the limb are readily achieved, without systemic side-effects. However, regional toxicity can lead to considerable morbidity and fu...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-199606000-00010

    authors: Thompson JF,Eksborg S,Kam PC,Ingvar C,Yau DF,Lai DT,Ramzan I

    更新日期:1996-06-01 00:00:00

  • A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.

    abstract::The presence of substantial amounts of GM3 ganglioside on human melanomas and other tumours, together with its peculiar biological properties, makes this glycolipid a unique target for cancer immunotherapy. B16 mouse melanoma expresses GM3 and constitutes an appropriate model for the development of novel GM3-based vac...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200106000-00003

    authors: Carr A,Mazorra Z,Alonso DF,Mesa C,Valiente O,Gomez DE,Perez R,Fernandez LE

    更新日期:2001-06-01 00:00:00

  • Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.

    abstract::To date, no study of melanoma patients who have undergone delayed lymph node dissection (DLND) has focused on the independent prognostic factors of overall survival, as calculated from surgery on the primary. Using Kaplan-Meier estimates and Cox's proportional hazard model, the significance of prognostic factors was e...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200010000-00011

    authors: Kretschmer L,Preusser KP,Marsch WC,Neumann C

    更新日期:2000-10-01 00:00:00

  • Phase I-II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities.

    abstract::Between 1983 and 1990, 59 patients with malignant melanoma were retrospectively reviewed to assess the safety, efficacy and the maximal tolerated dose of cisplatin used in hyperthermic isolated limb perfusion. The median follow-up was 29 months (range 3-54 months). The local recurrence rate was 12% in Stage I, 33% in ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-199104000-00007

    authors: Hajarizadeh H,Mueller CR,Woltering EA,Small K,Fletcher WS

    更新日期:1991-04-01 00:00:00

  • Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.

    abstract::Recently, we reported on the associations of seven single nucleotide polymorphisms (SNPs) in the promoter region of MMP1 gene with susceptibility to cutaneous melanoma (CM). Considering the reported correlation between MMP1 expression and melanoma progression, we hypothesized that these promoter SNPs might affect CM p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32834fc46b

    authors: Liu H,Wei Q,Gershenwald JE,Prieto VG,Lee JE,Duvic M,Grimm EA,Wang LE

    更新日期:2012-04-01 00:00:00

  • A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

    abstract::We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion i...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000036

    authors: Lau DK,Andrews MC,Turner N,Azad AA,Davis ID,Cebon JS

    更新日期:2014-04-01 00:00:00

  • Superantigen-induced lysis of melanoma cells.

    abstract::Superantigens like the Staphylococcus enterotoxin A (SEA) can direct cytotoxic T lymphocytes expressing certain T cell receptor V beta regions to lyse MHC class II-positive target cells. This superantigen-dependent cellular cytotoxicity (SDCC) has been extended to MHC class II-negative tumour cells by targeting T cell...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199706000-00005

    authors: Krull F,Holzer U,Ihle J,Bethge W,Fierlbeck G,Kalland T,Dohlsten M,Niethammer D,Dannecker GE

    更新日期:1997-06-01 00:00:00

  • Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?

    abstract::Isolated limb perfusion (ILP) with melphalan is used to treat recurrent melanoma. This study aimed to develop a microdialysis technique for melphalan tissue concentration measurement during ILP. The effects of melphalan concentration (50-600 microg/ml), microdIalysis flow rate (0.55-17.5 microl/min), probe length (5-5...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Wu ZY,Smithers BM,Anderson C,Roberts MS

    更新日期:2000-02-01 00:00:00

  • Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.

    abstract::Selective inhibition of the mutant BRAF protein is a highly promising therapeutic approach for melanoma patients carrying the BRAF mutation. Despite the remarkable clinical response, most patients develop resistance and experience tumour regrowth. To clarify the molecular background of BRAF inhibitor resistance, we ge...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000588

    authors: Szász I,Koroknai V,Kiss T,Vízkeleti L,Ádány R,Balázs M

    更新日期:2019-08-01 00:00:00

  • Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.

    abstract::Accumulating evidence has suggested that the XRCC1 Arg399Gln and Arg194Trp polymorphisms might be related to cutaneous melanoma susceptibility. However, epidemiologic findings have been inconsistent. We have assessed reported studies by meta-analysis to perform a more precise estimation of the association between the ...

    journal_title:Melanoma research

    pub_type: 杂志文章,meta分析

    doi:10.1097/CMR.0000000000000246

    authors: Jiang H,Xu W,Zhang F,Wei L,Wang Y,Wang Y,Liu C

    更新日期:2016-06-01 00:00:00

  • Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.

    abstract::Glutathione (GSH) is the major non-protein thiol in cells that plays a critical role against damage from electrophilic agents such as alkylating drugs. Selective therapeutic GSH elevation in normal but not in tumour cells has been suggested as a means of protecting host tissues against more intense doses of chemothera...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: del Olmo M,Alonso-Varona A,Castro B,Calle Y,Bilbao P,Palomares T

    更新日期:2000-04-01 00:00:00

  • Overexpression of HER-2 in thick melanoma.

    abstract::In this study we evaluated the overexpression status of HER-2 and its prognostic significance on survival in patients with thick cutaneous malignant melanoma. The immuno-alkaline phosphatase antigen detection technique was applied to archival diagnostic material from 51 patients with primary lesions measuring >or= 10 ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200204000-00006

    authors: Eliopoulos P,Mohammed MQ,Henry K,Retsas S

    更新日期:2002-04-01 00:00:00

  • Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

    abstract::Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000108

    authors: Berrocal A,Arance A,Lopez Martin JA,Soriano V,Muñoz E,Alonso L,Espinosa E,Lopez Criado P,Valdivia J,Martin Algarra S,Spanish Melanoma Group.

    更新日期:2014-12-01 00:00:00